Physician profile
Rose L Romulus
NPI 1770909236
$1,819.20
in general payments reported to CMS, 2019-2025
16 companies · $545 in 2025
The $545 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.15 · 2022: $374 · 2023: $520 · 2024: $299 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $727.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $214.00 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Lilly USA, LLC | $169.38 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.69 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $136.80 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Novo Nordisk INC | $70.24 | 2024 | Rybelsus |
| Amgen INC. | $67.38 | 2023-2025 | Repatha, Otezla, Otezla |
| Indivior INC. | $58.21 | 2022-2023 | Perseris |
| Abbvie INC. | $50.94 | 2022-2025 | |
| Shield Therapeutics INC | $35.28 | 2023-2025 | Accrufer |
| Pfizer INC. | $31.36 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $27.52 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $21.50 | 2021 | |
| Exact Sciences Corporation | $20.59 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2023 | Xifaxan, Trulance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.66 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Romulus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.